Citations

Clear

299 citation(s) found for "Solomon, B".

Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3
Mocci, Evelina, Kundu, Prosenjit, Wheeler, William, Arslan, Alan A. , Beane-Freeman, Laura E., Bracci, Paige M., Brennan, Paul , Canzian, Federico , Du, Mengmeng, Gallinger, Steven, Goodman, Phyllis J., Kooperberg, Charles, Marchand, Loic Le, Neale, Rachel E., Shu, Xiao-Ou, Visvanathan, Kala , White, Emily, Zheng, Wei, Albanes, Demetrius, Andreotti, Gabriella, Babic, Ana, Berndt, Sonja I., Bueno-de-Mesquita, Bas, Buring, Julie E., Campa, Daniele, Chanock, Stephen J., Childs, Erica J., Fuchs, Charles S., Gaziano, J. Michael, Giovannucci, Edward L., Goggins, Michael G., Hartge, Patricia, Hassan, Manal M., Holly, Elizabeth A., Hoover, Robert N., Kurtz, Robert C., Lee, I-Min, Ng, Kimmie, Oberg, Ann L. , Panico, Salvatore, Peters, Ulrike, Porta, Miquel, Rabe, Kari G. , Riboli, Elio, Rothman, Nathaniel, Scelo, Ghislaine, Sesso, Howard D. , Silverman, Debra T., Stevens, Victoria L. , Strobel, Oliver , Thompson, Ian M., Tjønneland, Anne , Trichopoulou, Antonia, Wactawski‐Wende, Jean , Wentzensen, Nicolas, Wilkens, Lynne R., Yuan, Fangcheng , Zeleniuch-Jacquotte, Anne, Li, Donghui , Jacobs, Eric J., Petersen, Gloria M., Wolpin, Brian M., Risch, Harvey A., Kraft, Peter, Chatterjee, Nilanjan, Ríboli, Elio , Zeleniuch‐Jacquotte, Anne , Thompson, Ian M. , Mocci, Evelina , Porta, Miquel , Giles, Graham G , Visvanathan, Kala , Bamlet, William R , Blackford, Amanda , Duell, Eric J , Hung, Rayjean J , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Chaffee, Kari G. , Sesso, Howard D , Stevens, Victoria L , Strobel, Oliver , Tjønneland, Anne , Van Den Eeden, Stephen K , Wactawski-Wende, Jean , Yu, Herbert , Yuan, Fangcheng , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Arslan, Alan A , Canzian, Federico , Riboli, Elio , Porta, Miquel , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Kundu, Prosenjit, Wheeler, William, Beane-Freeman, Laura E., Bracci, Paige M., Brennan, Paul , Du, Mengmeng, Gallinger, Steven, Goodman, Phyllis J., Kooperberg, Charles, Marchand, Loic Le, Neale, Rachel E., Shu, Xiao-Ou, White, Emily, Zheng, Wei, Albanes, Demetrius, Andreotti, Gabriella, Babic, Ana, Berndt, Sonja I., Bueno-de-Mesquita, Bas, Buring, Julie E., Campa, Daniele, Chanock, Stephen J., Childs, Erica J., Fuchs, Charles S., Gaziano, J. Michael, Giovannucci, Edward L., Goggins, Michael G., Hartge, Patricia, Hassan, Manal M., Holly, Elizabeth A., Hoover, Robert N., Kurtz, Robert C., Lee, I-Min, Ng, Kimmie, Panico, Salvatore, Peters, Ulrike, Rothman, Nathaniel, Scelo, Ghislaine, Silverman, Debra T., Thompson, Ian M., Trichopoulou, Antonia, Wentzensen, Nicolas, Wilkens, Lynne R., Jacobs, Eric J., Petersen, Gloria M., Wolpin, Brian M., Risch, Harvey A., Kraft, Peter, Chatterjee, Nilanjan

Mayo Clinic

Cancer Research | February 11, 2021 | Volume: 81 | Issue: 11 | Pages: 3134-3143

10.1158/0008-5472.can-20-3267 | PMID 33574088 Get It

Abstract Germline variation and smoking are independently associated with pancreatic ductal adenocarcinoma (PDAC). We conducted genome-wide smoking interaction analysis of PDAC using genotype data from four previous genome-wide association studies in individuals of European ancestry (7,937 cases and 11,774 controls). Examination of expression quantitative trait loci data from the Genotype-Tissue Expression Project followed by colocalization analysis was conducted to determine whether there was support for common SNP(s) underlying the observed associations. Statistical tests were two sided and P < 5 × 10–8 was considered statistically significant. Genome-wide significant evidence of qualitative interaction was identified on chr2q21.3 in intron 5 of the transmembrane protein 163 (TMEM163) and upstream of the cyclin T2 (CCNT2). The most significant SNP using the Empirical Bayes method, in this region that included 45 significantly associated SNPs, was rs1818613 [per allele OR in never smokers 0.87, 95% confidence interval (CI), 0.82–0.93; former smokers 1.00, 95% CI, 0.91–1.07; current smokers 1.25, 95% CI 1.12–1.40, Pinteraction = 3.08 × 10–9). Examination of the Genotype-Tissue Expression Project data demonstrated an expression quantitative trait locus in this region for TMEM163 and CCNT2 in several tissue types. Colocalization analysis supported a shared SNP, rs842357, in high linkage disequilibrium with rs1818613 (r2 = 0. 94) driving both the observed interaction and the expression quantitative trait loci signals. Future studies are needed to confirm and understand the differential biologic mechanisms by smoking status that contribute to our PDAC findings. Significance: This large genome-wide interaction study identifies a susceptibility locus on 2q21.3 that significantly modified PDAC risk by smoking status, providing insight into smoking-associated PDAC, with implications for prevention.
Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens
Kavanaugh, Arthur, Tomar, Russell H., Reveille, John D. , Solomon, Daniel H. , Homburger, Henry A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 1 | Pages: 71-81

10.5858/2000-124-0071-gfcuot | PMID 10629135 Get It

Abstract The following guideline presents a series of recommendations based on published medical literature for use of the antinuclear antibody (ANA) test and tests for specific autoantibodies to nuclear antigens in the diagnostic evaluation, prognostic assessment, and monitoring of patients with systemic rheumatic diseases. The guideline emphasizes the need for clinical evaluation to improve the usefulness of test results in patient management. Consideration is given to appropriate use of the generic ANA test in the initial evaluation of patients with signs and symptoms of a systemic rheumatic disease, the evaluation of patients suspected of having lupus erythematosus, use in clinical situations in which the ANA test is required to establish a disease diagnosis, and identification of clinical situations in which the ANA test has little value. Sections are also devoted to recommendations aimed at improving the analytic methods used to detect and measure ANA and specific autoantibodies to nuclear antigens and to the appropriate use of tests for specific autoantibodies in several disease situations that commonly occur in patients with suspected or documented systemic rheumatic diseases. Emphasis is placed on the use of these tests only in situations in which the test results can be expected to provide information necessary for clinical decision making. Those tests of limited medical usefulness and situations in which test results are likely to be misleading are also identified.
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Ng, Casey K. , Loo, Ronald K., Jacobsen, Steven J. , Tan, Wei Shen , Kelly, John D. , Lough, Tony, Darling, David, Kessel, Kim E.M. van, Jong, Joep J. de , Criekinge, Wim Van , Hiar, Andrew M., Boorjian, Stephen A. , Barocas, Daniel A. , Svatek, Robert S. , Woldu, Solomon L , Slezak, Jeff M. , Shariat, Shahrokh F. , Brown, Sarah, Lotan, Yair

Mayo Clinic

Journal of Urology | December 24, 2020 | Volume: 205 | Issue: 5 | Pages: 1387-1393

10.1097/ju.0000000000001550 | PMID 33356483 Get It

Associations Between Atrial Cardiopathy and Cerebral Amyloid: The ARIC‐PET Study
Johansen, Michelle C. , Mosley, Thomas H. , Knopman, David S. , Wong, Dean F. , Ndumele, Chiadi E. , Shah, Amil M. , Solomon, Scott D. , Mosley, Thomas H. , Knopman, David S. , Johansen, Michelle C , Shah, Amil , Solomon, Scott David , Gottesman, Rebecca F.

Mayo Clinic

Journal of the American Heart Association | December 8, 2020 | Volume: 9 | Issue: 24 | Pages: No page available

10.1161/jaha.120.018399 | PMID 33289449 Get It

Background Atrial fibrillation (AF) is a risk factor for cognitive decline, possibly from silent brain infarction. Left atrial changes in structure or function (atrial cardiopathy) can lead to AF but may impact cognition independently. It is unknown if AF or atrial cardiopathy also acts on Alzheimer disease–specific mechanisms, such as deposition of β‐amyloid. Methods and Results A total of 316 dementia‐free participants from the ARIC (Atherosclerosis Risk in Communities) study underwent florbetapir positron emission tomography, electrocardiography, and 2‐dimensional echocardiography. Atrial cardiopathy was defined as ≥1: (1) left atrial volume index >34 mL/m 2 ; (2) P‐wave terminal force >5000 µV×ms; and (3) serum NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >250 pg/mL. Cross‐sectional associations between global cortical β‐amyloid (>1.2 standardized uptake value ratio) and adjudicated history of AF and atrial cardiopathy, each, were evaluated using multivariable logistic regression. Participants (mean age, 76 years) were 56% women and 42% Black individuals. Odds of elevated florbetapir standardized uptake value ratio were significantly increased among those with atrial cardiopathy (odds ratio, 1.81; 95% CI, 1.02–3.22) and doubled for those with enlarged left atrial volume index after adjustment for demographics/risk factors (95% CI, 1.04–4.61). There was no association between P‐wave terminal force or NT‐proBNP and elevated florbetapir standardized uptake value ratio, nor between AF and elevated standardized uptake value ratio. Conclusions Among healthy, nondemented community‐dwelling older individuals, we report an association between atrial cardiopathy, left atrial volume index, and elevated brain amyloid, by positron emission tomography, without a similar association in individuals with AF. Potential limitations include reverse causation and survival bias. Ongoing work will help determine if changes in cardiac structure and function precede or occur simultaneously with amyloid deposition.
Abstract IA-11: An exception to the rule: A coding functional variant at a pancreatic cancer GWAS locus
Jermusyk, Ashley , Zhong, Jun, Gordon, Naomi, Abdolalizadeh, Ehssan, O’Brien, Aidan , Collins, Irene , Eiser, Daina, Jacobs, Eric J. , Li, Donghui , Du, Mengmeng , Wolpin, Brian M. , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Zhong, Jun , Connelly, Katelyn E. , Perera, Sumeth , Zhang, Tongwu , Hoskins, Jason W. , Yuan, Chen , Risch, Harvey A. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Chanock, Stephen Jacob , Westlake, Christopher J. , Ámundadóttir, Laufey T.

Mayo Clinic

Cancer Research | November 17, 2020 | Volume: 80 | Issue: 22_Supplement | Pages: IA-11-IA-11

10.1158/1538-7445.panca20-ia-11 Get It

Abstract Genome wide association studies (GWAS) in 9,013 pancreatic cancer patients and 12,452 controls of European ancestry have discovered over 20 risk loci in the human genome. Here, we fine mapped one such locus on chromosome 16q23.1 in the vicinity of two Chymotrypsinogen precursor genes, CTRB1 and CTRB2. We fine-mapped this locus to rs72802365 (P=2.51x10-17, OR=1.36, 95% CI=1.31-1.40) and identified colocalization (PP=87%) with aberrant exon 5→7 CTRB2 splicing in pancreatic tissues. Imputation of a 584 bp insertion/deletion variant overlapping exon 6 of CTRB2 into the GWAS datasets resulted in a highly significant association with pancreatic cancer risk (P=2.83x10-16, OR=1.36, 95% CI=1.31-1.42), indicating that it may underlie this signal. Exon skipping attributable to the deletion (risk) allele introduces a premature stop codon in exon 7 of CTRB2, yielding a truncated chymotrypsin B2 protein that lacks chymotrypsin activity, is poorly secreted, and accumulates intracellularly in the endoplasmic reticulum (ER). The intracellular accumulation of a nonfunctional chymotrypsinogen B2 protein may lead to ER stress and pancreatic inflammation, which in turn, may explain the increased pancreatic cancer risk in carriers of CTRB2 exon 6 deletion alleles. Citation Format: Ashley Jermusyk, Jun Zhong, Naomi Gordon, Katelyn Connelly, Sumeth Perera, Ehssan Abdolalizadeh, Tongwu Zhang, Aidan O'Brien, Jason Hoskins, Irene Collins, Daina Eiser, Chen Yuan, Harvey Risch, Eric J. Jacobs, Donghui Li, Mengmeng Du, Rachael Stolzenberg-Solomon, Alison P. Klein, Jill P. Smith, Brian M. Wolpin, Stephen J. Chanock, Jianxin Shi, Gloria M. Petersen, Christopher Westlake, Laufey T. Amundadottir. An exception to the rule: A coding functional variant at a pancreatic cancer GWAS locus [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr IA-11.
Intratumoral Injection of Clostridium novyi -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
Jankú, Filip , Zhang, Halle Huihong, Pezeshki, Abdulmohammad, Goel, Sanjay , Helgason, Thorunn, Masters, Tyler, Hong, David S. , Piha‐Paul, Sarina A. , Karp, Daniel D. , Klang, Mark , Sakamuri, Divya, Raina, Anjali, Torrisi, Jean , Solomon, Stephen B. , Weissfeld, Alice S., Trevino, Ernest, DeCrescenzo, Gary, Collins, Amanda, Miller, Maria, Salstrom, Jennifer L., Korn, Ronald L. , Zhang, Linping , Saha, Saurabh , Leontovich, Alexey A. , Tung, David, Kreider, Brent L. , Varterasian, Mary , Khazaie, Khashayarsha , Gounder, Mrinal M. , Hong, David S , Klang, Mark , Kreider, Brent , Goel, Sanjay , Piha-Paul, Sarina A , Pezeshki, Abdulmohammad , Murthy, Ravi , Wang‐Gillam, Andrea , Shepard, Dale R. , Huang, Steven Y. , Collins, Amanda, Tung, David

Mayo Clinic

Clinical Cancer Research | October 12, 2020 | Volume: 27 | Issue: 1 | Pages: 96-106

10.1158/1078-0432.ccr-20-2065 | PMID 33046513 Get It

Abstract Purpose: Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response in animals, which warrants clinical investigation. Patients and Methods: This first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection of C. novyi-NT across 6 dose cohorts (1 × 104 to 3 × 106 spores, 3+3 dose-escalation design) to determine dose-limiting toxicities (DLT), and the maximum tolerated dose. Results: Among 24 patients, a single intratumoral injection of C. novyi-NT led to bacterial spores germination and the resultant lysis of injected tumor masses in 10 patients (42%) across all doses. The cohort 5 dose (1 × 106 spores) was defined as the maximum tolerated dose; DLTs were grade 4 sepsis (n = 2) and grade 4 gas gangrene (n = 1), all occurring in three patients with injected tumors >8 cm. Other treatment-related grade ≥3 toxicities included pathologic fracture (n = 1), limb abscess (n = 1), soft-tissue infection (n = 1), respiratory insufficiency (n = 1), and rash (n = 1), which occurred across four patients. Of 22 evaluable patients, nine (41%) had a decrease in size of the injected tumor and 19 (86%) had stable disease as the best overall response in injected and noninjected lesions combined. C. novyi-NT injection elicited a transient systemic cytokine response and enhanced systemic tumor-specific T-cell responses. Conclusions: Single intratumoral injection of C. novyi-NT is feasible. Toxicities can be significant but manageable. Signals of antitumor activity and the host immune response support additional studies of C. novyi-NT in humans.
Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk
Ghoneim, Dalia, Zhu, Jingjing , Murff, Harvey J. , Ye, Fei , Khankari, Nikhil K. , Haycock, Philip , Antwi, Samuel O. , Yang, Yaohua , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Rabe, Kari G. , Duggal, Priya , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hassan, Manal M. , Helzlsouer, Kathy J. , Holly, Elizabeth A. , Hoover, Robert N. , Katske, Verena, Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Oberg, Ann L. , Porta, Miquel , Rothman, Nathaniel , Sesso, Howard D. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Wolpin, Brian M. , Jacobs, Eric J. , Petersen, Gloria M. , Stolzenberg-Solomon, Rachel Z., Wu, Lang , Haycock, Philip , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Visvanathan, Kala , Bamlet, William R , Brennan, Paul , Chaffee, Kari G. , Hackert, Thilo , Katzke, Verena , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Sesso, Howard D , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Klein, Alison P , Antwi, Samuel O , Murphy, Neil , Porta, Miquel , Duggal, Priya , Zheng, Wei , Long, Jirong , Setiawan, Veronica Wendy , Wilkens, Lynne R. , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , White, Emily , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Brais, Lauren K , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Rothman, Nathaniel , Silverman, Debra T. , Thompson, Ian M. , Wang, Xiaoliang , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Duell, Eric J. , Risch, Harvey A. , Ámundadóttir, Laufey T. , Kraft, Peter , Klein, Alison P. , Shu, Xiao‐Ou , Yang, Yaohua

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 23, 2020 | Volume: 29 | Issue: 12 | Pages: 2735-2739

10.1158/1055-9965.epi-20-0651 | PMID 32967863 Get It

Abstract Background: Whether circulating polyunsaturated fatty acid (PUFA) levels are associated with pancreatic cancer risk is uncertain. Mendelian randomization (MR) represents a study design using genetic instruments to better characterize the relationship between exposure and outcome. Methods: We utilized data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case–Control Consortium, involving approximately 9,269 cases and 12,530 controls of European descent, to evaluate associations between pancreatic cancer risk and genetically predicted plasma n-6 PUFA levels. Conventional MR analyses were performed using individual-level and summary-level data. Results: Using genetic instruments, we did not find evidence of associations between genetically predicted plasma n-6 PUFA levels and pancreatic cancer risk [estimates per one SD increase in each PUFA-specific weighted genetic score using summary statistics: linoleic acid odds ratio (OR) = 1.00, 95% confidence interval (CI) = 0.98–1.02; arachidonic acid OR = 1.00, 95% CI = 0.99–1.01; and dihomo-gamma-linolenic acid OR = 0.95, 95% CI = 0.87–1.02]. The OR estimates remained virtually unchanged after adjustment for covariates, using individual-level data or summary statistics, or stratification by age and sex. Conclusions: Our results suggest that variations of genetically determined plasma n-6 PUFA levels are not associated with pancreatic cancer risk. Impact: These results suggest that modifying n-6 PUFA levels through food sources or supplementation may not influence risk of pancreatic cancer.
Advanced Respiratory Support in the Contemporary Cardiac ICU
Metkus, Thomas S. , Miller, P. Elliott , Alviar, Carlos L. , Baird-Zars, Vivian M., Bohula, Erin A. , Cremer, Paul , Keeley, Ellen C. , Kontos, Michael C. , Menon, Venu , Park, Jeong‐Gun , Schulman, Steven P. , Katz, Jason N. , Bohula, Erin A , Cremer, Paul C , Gerber, Daniel , Jentzer, Jacob C. , Roswell, Robert O. , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

Critical Care Explorations | September 18, 2020 | Volume: 2 | Issue: 9 | Pages: e0182

10.1097/cce.0000000000000182 | PMID 33235999 Get It

Objectives: The medical complexity and critical care needs of patients admitted to cardiac ICUs are increasing, and prospective studies examining the underlying cardiac and noncardiac diagnoses, the management strategies, and the prognosis of cardiac ICU patients with respiratory failure are needed. Design: Prospective cohort study. Setting: The Critical Care Cardiology Trials Network is a research collaborative of cardiac ICUs across the United States and Canada. Patients: We included all medical cardiac ICU admissions at 25 cardiac ICUs during two consecutive months annually at each center from 2017 to 2019. Measurements: We evaluated the use of advanced respiratory therapies including invasive mechanical ventilation, noninvasive ventilation, and high-flow nasal cannula versus no advanced respiratory support across admission diagnoses and the association with in-hospital mortality. Main Results: Of 8,240 cardiac ICU admissions, 1,935 (23.5%) were treated with invasive mechanical ventilation, 573 (7.0%) with noninvasive ventilation, and 281 (3.4%) with high-flow nasal cannula. Admitting diagnoses among those with advanced respiratory support were diverse including general medical problems in patients with heart disease as well as primary cardiac problems. In-hospital mortality was higher in patients who received invasive mechanical ventilation (38.1%; adjusted odds ratio, 2.53; 2.02–3.16) and noninvasive ventilation or high-flow nasal cannula (8.8%; adjusted odds ratio, 2.25; 1.73–2.93) compared with patients without advanced respiratory support (4.6%). Reintubation rate was 7.6%. The most common variables associated with respiratory insufficiency included heart failure, infection, chronic obstructive pulmonary disease, and pulmonary vascular disease. Conclusions: One-third of cardiac ICU admissions receive respiratory support with associated increased mortality. These data provide benchmarks for quality improvement ventures in the cardiac ICU, inform cardiac critical care training and staffing patterns, and serve as foundation for future studies aimed at improving outcomes.
Abstract 1200: Associations between genetically predicted blood protein biomarkers and pancreatic ductal adenocarcinoma risk
Zhu, Jingjing , Shu, Xiao-Ou , Liu, Duo , Du, Mengmeng , Goodman, Phyllis J. , Li, Donghui , Bracci, Paige M. , Gallinger, Steven, Eeden, Stephen Van Den, Wolpin, Brian M. , Scélo, Ghislaine , Visvanatha, Kala, Haiman, Christopher A. , Petersen, Gloria M. , Zheng, Wei , Wu, Lang , Zheng, Wei , Guo, Xingyi , Bao, Jiandong , Milne, Roger L. , Giles, Graham G. , Wu, Chong , White, Emily , Risch, Harvey A. , Malats, Núria , Duell, Eric J. , Katzke, Verena , Neale, Rachel Ε. , Arslan, Alan A. , Canzian, Federico , Kooperberg, Charles , Freeman, Laura E. Beane , Marchand, Loı̈c Le , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Ámundadóttir, Laufey T. , Cai, Qiuyin , Long, Jirong , Shu, Xiao‐Ou

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1200-1200

10.1158/1538-7445.am2020-1200 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of most lethal malignancies with few known risk factors and biomarkers. Identification of disease biomarkers is critical for understanding the pathogenesis of this cancer and identifying high risk individuals for close surveillance. Several blood protein biomarkers have been linked to PDAC in previous studies, but these studies have assessed only a limited number of biomarkers usually in small samples. To identify novel circulating protein biomarkers of PDAC, we studied 8,280 cases and 6,728 controls of European descent from the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium, by using genetic instruments. Protein quantitative trait loci (pQTLs) for 1,226 plasma proteins identified in a large INTERVAL study of 3,301 healthy European descendants were used as instruments to evaluate associations between genetically predicted protein levels and PDAC. For proteins showing a significant association, we further conducted conditional analysis with adjustments for previously identified risk variants to assess whether the observed associations between genetically predicted protein concentrations and PDAC risk were independent of the risk variants identified in genome-wide association studies (GWAS). Furthermore, for the proteins that were associated with PDAC risk, we performed an enrichment analysis of the genes encoding these proteins to examine whether they are enriched in specific pathways, functions or networks. We observed associations between predicted concentrations of 38 proteins and PDAC risk at a false discovery rate of < 0.05, including those of 23 proteins that showed a significant association even after Bonferroni correction (4.08 × 10−5). These include Histo-blood group ABO system transferase encoded by ABO, which has been previously implicated as a potential target gene of PDAC risk variant identified in GWAS. Eight of the identified proteins (Beta-crystallin B2, Dedicator of cytokinesis protein 9, VIP36-like protein, Erythrocyte band 7 integral membrane protein, Tensin-2, Transmembrane protease serine 11D, Alcohol dehydrogenase 1B, and C-X-C motif chemokine 10) were associated with PDAC risk after conditioning on previously reported pancreatic cancer risk variants (odds ratios ranged from 0.79 to 1.52, P-values from 1.28 × 10−3 to 6.47 × 10−4). Pathway enrichment analysis showed that the encoding genes for the implicated proteins were significantly enriched in cancer-related pathways, such as STAT3 and IL-15 production. In conclusion, we identified 38 protein biomarker candidates for PDAC risk, which if validated by additional studies, may contribute to the etiological understanding of PDAC tumor development. Citation Format: Jingjing Zhu, Xiang Shu, Xingyi Guo, Duo Liu, Jiandong bao, Roger Milne, Graham G Giles, Chong Wu, Mengmeng Du, Emily White, Harvey A Risch, Nuria Malats, Eric J. Duell, Phyllis J. Goodman, Donghui Li, Paige Bracci, Verena Katzke, Rachel E Neale, Steven Gallinger, Stephen Van Den Eeden, Alan Arslan, Federico Canzian, Charles Kooperberg, Brian Wolpin, Laura Beane-Freeman, Ghislaine Scelo, Kala Visvanatha, Christopher A. Haiman, Loïc Le Marchand, Herbert Yu, Gloria M Petersen, Rachael Stolzenberg-Solomon, Alison P Klein, Laufey T Amundadottir, Qiuyin Cai, Jirong Long, Xiao-Ou Shu, Wei Zheng, Lang Wu. Associations between genetically predicted blood protein biomarkers and pancreatic ductal adenocarcinoma risk [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1200.
Abstract 1213: Genome-wide interaction scan identifies gene by smoking interaction at 2q21.3 for pancreatic cancer risk
Kundu, Prosenjit , Wheeler, William , Li, Donghui , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Chatterjee, Nilanjan , consortia, The PanScan and Panc4, Mocci, Evelina , Ámundadóttir, Laufey T. , Risch, Harvey A. , Kraft, Peter , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z. , consortia, The PanScan and Panc4

Mayo Clinic

Cancer Research | September 3, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1213-1213

10.1158/1538-7445.am2020-1213 Get It

Abstract Introduction: Pancreatic cancer is the seventh leading cause of cancer death worldwide with pancreatic ductal adenocarcinoma (PDAC) being the most common subtype (>90%). Inherited genetic changes and cigarette smoking are established independent risk factors of PDAC. Methods: We conducted a genome-wide gene by smoking interaction analysis of PDAC risk among 7,937 PDAC cases and 12,389 controls of European ancestry from the Pancreatic Cancer Cohort (PanScan) and Pancreatic Cancer Case-Control Consortia (PanC4) with complete genotyping and smoking data. Over 6,769,447 SNPs met our inclusion criteria of imputation score >0.5 and MAF >0.05 after imputation to phase 3 1000G and were included in our analysis. We evaluated the gene-environment interactions using the empirical Bayes method which allows data-adaptive relaxation of the gene-environment independence assumption. The logistic regression model was adjusted for age, sex, top principal components for each phase, study and study region (PanScan only). The analysis was conducted separately for the PanScan and PanC4 GWAS studies, using a score test to efficiently incorporate expected SNP dosages. The estimates were then combined using a fixed-effect meta-analysis. We examined expression quantitative trait locus using data from the NIH Genotype-Tissue Expression (GTEx) database. We considered a P-value < 5.0 × 10−8 statistically significant. Results: We found a genome-wide significant qualitative interaction with the SNP rs1818613 by smoking status (P-value <5 × 10−9) where, compared to the G allele, the T allele was associated with a reduced risk PDAC in never smokers (per T allele OR, 0.87; 95% CI, 0.82-0.93), had no association in former smokers (OR, 1.00; 95% CI, 0.91-1.07) and was associated with an increased risk in current smokers (OR, 1.25; 95% CI, 1.12-1.40). This SNP is located on chromosome 2q21.3 in intron 5 of the transmembrane protein 163 (TMEM163) gene and upstream of the cyclin T2 (CCNT2) gene. More than 40 additional SNPs within 100Kbp and in high LD (r2 > 0.8) with rs1818613 provided significant evidence of interaction by smoking status for PDAC risk. rs1818613 was associated with differential expression of TMEM163 in several tissues: for T allele compared with the G allele there was increased expression in the heart, pituitary, whole blood, and esophagus-muscularis and decreased expression in the testis tissues (P-value < 3 × 10−11). It was also associated with decreased CCNT2 expression in the tibial nerve tissue (P-value = 1.9 × 10−9). Conclusions: Our work supports that the genetic variation in the region, in conjunction with cigarette smoking, influences PDAC risk. Future studies are needed to explore this association in other smoking-related cancers and to understand the biological mechanism of such association. Citation Format: Prosenjit Kundu, Evelina Mocci, William Wheeler, Laufey T. Amundadottir, Donghui Li, Eric J. Jacobs, Gloria M. Petersen, Brian M. Wolpin, Harvey A. Risch, Peter Kraft, Nilanjan Chatterjee, Alison P. Klein, Rachael Z. Stolzenberg-Solomon, The PanScan and Panc4 consortia. Genome-wide interaction scan identifies gene by smoking interaction at 2q21.3 for pancreatic cancer risk [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1213.